Related Experiment Video

Updated: May 15, 2026

Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells
10:21

Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells

Published on: January 5, 2018

CDK6 inactivation counteracts CALR-mutant-induced MPN evolution and sensitizes MPN stem cells to interferon-α

Brian Ringhofer1, Wolfram Polzer1, Michaela Prchal-Murphy1

  • 1Department of Biological Sciences and Pathobiology, Institute of Pharmacology and Toxicology University of Veterinary Medicine Vienna Vienna Austria.

Hemasphere
|May 14, 2026
PubMed

Insights

In myeloproliferative neoplasms (MPNs), inhibiting cyclin-dependent kinase 6 (CDK6) with palbociclib enhances interferon-alpha (IFNα) therapy. This combination shows improved efficacy and a better safety profile in MPN cells.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Interferon-alpha (IFNα) is a key therapy for myeloproliferative neoplasms (MPNs) with JAK/STAT activation.
  • Patient responses to IFNα vary, necessitating combination strategies.
  • Cyclin-dependent kinase 6 (CDK6) has been linked to IFN signaling pathways.

Purpose of the Study:

  • To investigate the role of CDK6 inhibition in enhancing IFN responsiveness in MPN cells.
  • To evaluate the therapeutic potential of combining CDK6 inhibitors with pegylated IFNα (pegIFNα) in MPNs.

Main Methods:

  • Utilized CALRdel52 knockin mice for genetic ablation of Cdk6.
  • Assessed MPN cell apoptosis and proliferation in vitro and in vivo.
  • Pharmacologic inhibition of CDK6 with palbociclib in combination with pegIFNα.
  • Analyzed CDK6 and IFNAR1 expression in MPN patient samples.

Main Results:

  • Genetic ablation of Cdk6 in MPN cells reduced spleen weight and platelet counts, inducing interferon-associated programs and upregulating IFNAR1.
  • CDK6 inhibition synergized with pegIFNα, inhibiting MPN cell growth.
  • Lower CDK6 expression in MPN patients correlated with higher IFNAR1 and stronger responses to the combination therapy.
  • The combination therapy demonstrated a favorable therapeutic window with reduced cytotoxicity in control cells.

Conclusions:

  • CDK6 acts as a brake on IFN signaling in MPN cells.
  • Combining CDK6 inhibition (palbociclib) with pegIFNα enhances anti-neoplastic effects in MPNs.
  • This combination represents a potential novel therapeutic strategy for improving MPN treatment.

More Related Videos

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm08:12

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Published on: December 22, 2016

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.